Westpac Banking Corp Takes $437,000 Position in Medpace Holdings, Inc. $MEDP

Westpac Banking Corp bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 826 shares of the company’s stock, valued at approximately $437,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. California State Teachers Retirement System increased its holdings in shares of Medpace by 22.1% in the first quarter. California State Teachers Retirement System now owns 26,042 shares of the company’s stock worth $12,505,000 after purchasing an additional 4,719 shares during the last quarter. Focus Partners Advisor Solutions LLC bought a new position in Medpace during the second quarter valued at approximately $1,685,000. Cerity Partners LLC boosted its stake in Medpace by 41.0% during the fourth quarter. Cerity Partners LLC now owns 80,973 shares of the company’s stock valued at $45,478,000 after buying an additional 23,530 shares during the last quarter. BlackRock Inc. purchased a new position in Medpace during the 2nd quarter valued at approximately $1,323,047,000. Finally, Local Pensions Partnership Investment Ltd grew its holdings in Medpace by 10.5% during the 2nd quarter. Local Pensions Partnership Investment Ltd now owns 42,000 shares of the company’s stock valued at $22,265,000 after buying an additional 4,000 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace News Summary

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace’s latest earnings exceeded expectations, with quarterly EPS of $4.25 versus the $3.98 consensus estimate and revenue of $707.33 million versus $689.51 million expected. Revenue increased 17.2% year over year, while management maintained fiscal 2026 EPS guidance of $17.25 to $17.95. Why Is Medpace Up Since Its Last Earnings Report?
• Neutral Sentiment: Analyst sentiment remains mostly cautious. Three analysts rate Medpace a Buy and 10 rate it Hold, with a consensus price target of $584.18. Several firms raised their targets following the earnings report, but those targets remain below the stock’s recent trading level. Medpace Analyst Ratings and Price Targets
• Negative Sentiment: Several insiders sold shares on August 19–20. CEO August J. Troendle sold 42,783 shares for roughly $26.3 million, reducing his holdings by about 7% across the reported transactions. Directors Brian T. Carley and Fred B. Davenport Jr. sold 5,000 and 7,283 shares, respectively, reducing their positions by approximately 15% and 66%. While insider sales do not necessarily indicate deteriorating fundamentals, the cluster of transactions may weigh on investor sentiment. Medpace Insider Buying and Selling
• Negative Sentiment: Valuation is demanding, with Medpace trading at approximately 36 times earnings and a PEG ratio of 2.73. The stock is also near the upper end of its 52-week range, increasing sensitivity to profit-taking and any slowdown in growth.

Wall Street Analyst Weigh In

A number of research firms have issued reports on MEDP. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $535.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Truist Financial increased their target price on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Royal Bank Of Canada raised their target price on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Finally, Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and upped their price target for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Three equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $584.18.

Insider Buying and Selling

In other news, Director Brian T. Carley sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the transaction, the director directly owned 27,825 shares of the company’s stock, valued at approximately $16,935,129.75. This trade represents a 15.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Cornelius P. Mccarthy III sold 1,140 shares of Medpace stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $605.37, for a total transaction of $690,121.80. Following the sale, the director directly owned 12,275 shares of the company’s stock, valued at $7,430,916.75. This represents a 8.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 122,261 shares of company stock worth $71,729,129 over the last 90 days. Corporate insiders own 20.50% of the company’s stock.

Medpace Trading Up 1.3%

NASDAQ:MEDP opened at $620.75 on Friday. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The company has a market cap of $17.33 billion, a price-to-earnings ratio of 36.39, a price-to-earnings-growth ratio of 2.77 and a beta of 1.15. The stock has a fifty day simple moving average of $550.16 and a 200-day simple moving average of $492.71.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same period in the prior year, the business posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.